Previous 10 | Next 10 |
Psychedelics have long been heralded for their numerous benefits , with recent studies showing that these substances may be useful in the treatment of various mental health conditions. These benefits have increased interest in these substances, with... Read more » About Psyche...
Summary Compass shares have lost 82% of their value over the past 12 months. The company is attempting to bring a form of therapy using the psychedelic drug psilocybin to market. A Phase 3 study protocol has been agreed with the FDA after a successful Phase 2 b study in TRD. ...
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide ...
The medicinal psychedelics space is continuing to grow as interest from the public increases and more research on these substances is conducted. Additionally, issued psychedelic patents portfolios are getting larger, with challenges to these patents being filed with the U.S. Patent and Tra...
Summary Today, we circle back on a small developmental firm called COMPASS Pathways after the stock was the subject of multiple buy recommendations last week. The company its advancing its lead candidate, which is a psychedelic drug treatment across several indications in mid to l...
The psychedelic story is coming back strong. All after Sen. Cory Booker tweeted, “Massive breakthroughs in medical studies with psilocybin and MDMA are showing strong promise for patients with PTSD, trauma, addiction, and serious depression. In the past, the failed War on Drugs has c...
Sen. Cory Booker (D-N.J.) is again pushing for easier access to psychedelic drugs, including psilocybin, the active psychedelic compound in "magic mushrooms," and MDMA, for terminally ill patients. In July, Booker and Sen. Rand Paul (R-Ky.) introduced legislation to clarify that t...
Summary Numinus has the potential to actively participate in a wave of consolidation that will roll through the psychedelics sector. Hype around psychedelic-assisted therapy is buffering against reality and investors are well-advised to tread cautiously. The Novamind acquisiti...
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment ...
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug for the treatment of major depressive disorder after r...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...